spacer gif spacer gif spacer gif spacer gif spacer gif
 QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online 27 January 2009
doi: 10.1242/jcs.042382


Journal of Cell Science 122, 489-498 (2009)
Published by The Company of Biologists 2009
This Article
Right arrow Summary Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JCS
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grob, A.
Right arrow Articles by Sirri, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grob, A.
Right arrow Articles by Sirri, V.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Involvement of SIRT7 in resumption of rDNA transcription at the exit from mitosis

Alice Grob1, Pascal Roussel1, Jane E. Wright2, Brian McStay2, Danièle Hernandez-Verdun1 and Valentina Sirri1,*

1 Institut Jacques Monod, UMR 7592 CNRS/Universités Paris 6 et 7, 2 Place Jussieu, 75251 Paris Cedex 05, France
2 Biomedical Research Center, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, Scotland, UK


Figure 1
View larger version (39K):
[in this window]
[in a new window]

 
Fig. 1. Endogenous SIRT7 co-localizes with UBF in interphase and mitotic HeLa cells. (A) Immunodetection of SIRT7, UBF and rDNA transcription sites was obtained in fixed interphase HeLa cells using anti-SIRT7-C-terminal (b,f), anti-UBF (c) and anti-BrdU (g) antibodies. Images were obtained using confocal laser microscopy. In merged images (d,h), yellow labeling indicates co-localization of green (SIRT7) and red (UBF or BrdU) signals. (B) SIRT7 signal obtained by immunofluorescence in control HeLa cells (a,b) is no longer detected after SIRT7 knockdown (c,d; arrow). (C) HeLa cells were synchronized in mitosis. Mitotic stages were determined on Z projections of focal planes by DAPI staining (a,e). SIRT7 (arrowheads b,f) and UBF (c,g) were immunodetected in mitotic HeLa cells. Immunofluorescence labelings were merged (d,h). (D) SIRT7 and UBF signal intensity was quantified in 30 NORs for each stage of mitosis. The ratios of the mean intensity value were quantified (P, 0.24±0.10; M, 0.11±0.03; A, 0.16±0.06; T, 0.28±0.06; T', 0.94±0.22). Bars, 10 µm. A, anaphase; M, metaphase; P, prophase; T, early telophase; T', late telophase.

 

Figure 2
View larger version (22K):
[in this window]
[in a new window]

 
Fig. 2. SIRT7 is recruited to pseudo-NORs via direct interaction with UBF. (A) GST and GST-SIRT7 pull-down assays were performed using whole HeLa cell extracts. 1% of extract used for each pull-down assay (Input), 5% of the proteins eluted after GST-SIRT7 pull-down assays and 5% of the proteins eluted after GST pull-down assays were submitted to 10% SDS-PAGE. Immunoblotting was performed using anti-PAF49, anti-PAF53, anti-RPA116/135, anti-RPA43, anti-TIF-1A/Rrn3, anti-UBF, anti-TTF-1 and anti-TBP antibodies. (B) GST and GST-SIRT7 pull-down assays were performed using 1 µg purified human UBF1 or UBF2. (C) The pseudo-NOR containing cell line 3D-1 was stained with anti-SIRT7-C-terminal and anti-UBF antibodies (a-d). Red and green labelings were merged (d). Pseudo-NORs are identified by arrowheads. Bar, 10 µm.

 

Figure 3
View larger version (53K):
[in this window]
[in a new window]

 
Fig. 3. Increase in SIRT7 signal corresponds to increased reactivity of antibodies to the SIRT7 C-terminal region. (A) In nocodazole-arrested HeLa cells treated (d-f) or not (a-c) with roscovitine (150 µM for 1 hour), SIRT7 and UBF were immunodetected using anti-SIRT7-C-terminal (c,f) and anti-UBF (b,e) antibodies. DNA was stained by DAPI and merged with red and green labelings (a,d). (B) SIRT7 signal intensity was quantified in 10 cells. The means of intensity value were quantified (Control: 0.25±0.06, Roscovitine: 0.83±0.15). (C) Cytoplasmic (lanes 1 and 3) and chromosome (lanes 2 and 4) fractions prepared from nocodazole-arrested HeLa cells treated (lanes 3 and 4) or not (lanes 1 and 2) with roscovitine were submitted to 10% SDS-PAGE. Immunoblotting was performed using anti-UBF, anti-SIRT7-N-terminal and anti-fibrillarin antibodies. (D) HeLa cells were synchronized in mitosis and mitotic stages were determined by DAPI staining (a,d,g). In immunofluorescence assays, SIRT7 and UBF were detected using anti-SIRT7-N-terminal (c,f,i) and anti-UBF (b,e,h) antibodies, respectively. Immunofluorescence labelings were merged with DAPI (a,d,g). Bars, 10 µm.

 

Figure 4
View larger version (69K):
[in this window]
[in a new window]

 
Fig. 4. Increased reactivity of antibodies to the SIRT7 C-terminal region occurs before, and independently of, onset of rDNA transcription. (A) Surrounded mitosis stages (M, T, T') of synchronized HeLa cells were determined on Z projections of focal planes by DAPI staining (a,e). SIRT7 and rDNA transcription sites were detected in fixed cells using respectively anti-SIRT7-C-terminal (b,f) and anti-BrdU (c,g) antibodies. Red and green labelings were merged (d,h). (B) Immunodetection of SIRT7 (c,h) and rDNA transcription sites (d,i) was performed in early G1 fixed cells in the absence (a-e) or presence (f-j) of AMD (0.1 µg/ml for 2 hours). Early G1 cells (arrows) were identified by phase-contrast (a,f) and DAPI staining (b,g). Arrowheads indicate metaphase cells. Immunofluorescence labelings were merged (e,j). Bars, 10 µm.

 

Figure 5
View larger version (50K):
[in this window]
[in a new window]

 
Fig. 5. Inhibition of CDK1-cyclin B induces increased reactivity of antibodies to the SIRT7 C-terminal region by SIRT7 dephosphorylation. (A) SIRT7 and rDNA transcription sites were immunodetected using anti-SIRT7-C-terminal (b,f,j,n) and anti-BrdU (c,g,k,o) antibodies in prometaphase mitotic HeLa cells, in the absence (a-d) or presence (e-h) of roscovitine (150 µM for 1 hour). Mitotic HeLa cells were also treated with AMD (0.1 µg/ml, i-l) or okadaic acid (0.5 µM, m-p) for 1 hour before addition of 150 µM roscovitine for 1 hour. Red and green labelings were merged (d,h,l,p). (B) Whole cell extracts from unsynchronized (U) or nocodazole-arrested mitotic (M) HeLa cells were submitted to 10% SDS-PAGE. Immunodetection of SIRT7 was performed using anti-SIRT7-N-terminal antibodies. (C) Whole cell extracts prepared from unsynchronized HeLa cells (Unsyn, lane 1) and from nocodazole-arrested mitotic HeLa cells (lanes 2-4) treated with okadaic acid (0.5 µM for 1 hour) (lane 4) or not (lane 3) before addition of roscovitine (150 µM for 1 hour) (lanes 3 and 4) were submitted to 7.5% Phos-tag SDS-PAGE. Immunodetection of SIRT7 was performed using anti-SIRT7-N-terminal antibodies. (D) SIRT7 presents a consensus CDK1 phosphorylation site (ATPLR) at amino acids 344-348 (red box). Blue boxes indicate the peptides against which anti-SIRT7-N-terminal antibodies (amino acids 32-51) and anti-SIRT7-C-terminal antibodies (amino acids 384–400) are directed. Bar, 10 µm.

 

Figure 6
View larger version (51K):
[in this window]
[in a new window]

 
Fig. 6. SIRT7 is involved in resumption of rDNA transcription at the exit from mitosis. (A) BrUTP incorporation in living cells was detected using anti-BrdU antibodies in interphase HeLa cells in the absence (a-b) or presence of AMD (0.1 µg/ml, c-d, or 4 µg/ml, e-f, for 2 hours) or sirtinol (100 µM for 6 hours, g-h). (B) Knockdown of SIRT1 and SIRT7 was analyzed by 10% SDS-PAGE and immunoblotting using anti-SIRT1 and anti-SIRT7-N-terminal antibodies. (C) SIRT1 and BrUTP incorporation were detected using anti-SIRT1 (b,e) and anti-BrdU (c,f) antibodies, respectively, in control (a-c) or SIRT1-depleted (d-f) HeLa cells. (D) SIRT7 and BrUTP incorporation were detected using anti-SIRT7 (b,e) and anti-BrdU (c,f) antibodies, respectively, in control (a-c) or SIRT7-depleted (d-f) HeLa cells. (E) SIRT7 and rDNA transcription sites were immunodetected using anti-SIRT7-C-terminal (b,f,j) and anti-BrdU (c,g,k) antibodies in prometaphase mitotic HeLa cells, in the absence (a-d) or presence (e-h) of roscovitine (150 µM for 1 hour). Mitotic HeLa cells were also treated with 100 µM sirtinol for 2 hours before addition of 150 µM roscovitine for 1 hour (i-l). Red and green labelings were merged (d,h,l). Bars, 10 µm.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




© The Company of Biologists Ltd 2009